Document is current
Any future updates will be listed below
-
Authors
Fakih, Hassan H. https://orcid.org/0000-0002-7598-0993
Zain UI Abideen, Mohammad
Rachid, Mohamad Omar
Gross, Katherine Y. https://orcid.org/0000-0002-3468-0345
Ormsby, Thomas J. R. https://orcid.org/0000-0003-4371-5316
Ross, Vella M.
Gagnon, Rosemary
Dahlke, Christopher
Furgal, Raymond C. https://orcid.org/0000-0002-4757-7339
Lochmann, Clemens https://orcid.org/0009-0005-3869-8242
Summers, Ashley https://orcid.org/0000-0002-5425-0457
Sleiman, Hanadi F. https://orcid.org/0000-0002-5100-0532
Fürst, Sylvia M.
Jackson, Shanté N.
Gordilho, Juliana O.
Bouix-Peter, Claire
Portal, Thibaud
Tang, Qi https://orcid.org/0000-0002-8913-0519
Harris, John E. https://orcid.org/0000-0002-7815-6430
Khvorova, Anastasia https://orcid.org/0000-0001-6928-8071
Blanchard, Carine https://orcid.org/0000-0002-3377-290X
Alterman, Julia F. https://orcid.org/0000-0002-6195-0857
- License Information
-
More Information
Article History
Received: 19 June 2025
Accepted: 20 January 2026
First Online: 3 February 2026
Competing interests
: The authors declare the following competing financial interest(s): The University of Massachusetts Chan Medical School holds patent or filed patent applications for the modulation of JAK1 with RNAi-based technologies (patent application number 18393044; Oligonucleotides for IFN-γ signaling pathway modulation; status pending), docosanoic acid conjugate (patent application number 17377632; Conjugated oligonucleotides for tissue-specific delivery) and dendritic conjugate for skin delivery (Patent application number 18592943; status pending). A.K. serves on the scientific advisory board of Alys Pharmaceuticals. J.E.H. owns equities in Rheos Medicines; is a founder of Alys Pharmaceuticals and Villaris Therapeutics. Select authors of this publication are listed as inventors on RNAi technology patents (HHF, M.Z.U., Q.T., J.F.A., J.E.H., A.K., M.Z.U., R.F., and K.G.) that have been licensed to biotech and pharmaceutical companies. The following patents are licensed by Aldena Therapeutics Ltd.: patent application number 18393044 (Oligonucleotides for IFN-γ signaling pathway modulation) and patent application number 17377632 (Conjugated oligonucleotides for tissue-specific delivery). C.B.P., C.B., J.O.G., and T.P. are executive employees of Alys Pharmaceuticals. SF is employed by Certara. SJ is employed by Altasciences. The remaining authors declare no competing interests.
